Abstract
The patient was diagnosed with ALL at the age of 13 years and was commenced on the UK ALL 2011 treatment regimen including intrathecal methotrexate, daunorubicin, PEG asparaginase and vincristine. She presented eight months after her initial diagnosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
